Response to: 'High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab' by Conticini et al

Ann Rheum Dis. 2022 Oct;81(10):e203. doi: 10.1136/annrheumdis-2020-218788. Epub 2020 Aug 19.

Authors

Sofia Ramiro^{1

2}, Rémy Mostard³, Robert Bm Landewé^{4

5}

Affiliations

¹ Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands sofiaramiro@gmail.com.
² Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
³ Department of Pulmonology, Zuyderland Medical Center, Heerlen, The Netherlands.
⁴ Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands.
⁵ Amsterdam Rheumatology Center, AMC, Amsterdam, The Netherlands.

PMID: 32816700
DOI: 10.1136/annrheumdis-2020-218788

No abstract available

Keywords: biological therapy; epidemiology; glucocorticoids.

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
COVID-19 Drug Treatment*
Humans
Methylprednisolone* / adverse effects
Methylprednisolone* / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
tocilizumab
Methylprednisolone